About: Ana Maria Gonzalez-Angulo

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ana Maria Gonzalez-Angulo Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

cancer researcher

Attributes	Values
rdf:type	Item
description	cancer researcher (en)
rdfs:label	Ana Maria Gonzalez-Angulo (da) Ana Maria Gonzalez-Angulo (de) Ana Maria Gonzalez-Angulo (en) Ana Maria Gonzalez-Angulo (fo) Ana Maria Gonzalez-Angulo (fr) Ana Maria Gonzalez-Angulo (is) Ana Maria Gonzalez-Angulo (kl) Ana Maria Gonzalez-Angulo (nb) Ana Maria Gonzalez-Angulo (nl) Ana Maria Gonzalez-Angulo (nn) Ana Maria Gonzalez-Angulo (sv)
skos:prefLabel	Ana Maria Gonzalez-Angulo (da) Ana Maria Gonzalez-Angulo (de) Ana Maria Gonzalez-Angulo (en) Ana Maria Gonzalez-Angulo (fo) Ana Maria Gonzalez-Angulo (fr) Ana Maria Gonzalez-Angulo (is) Ana Maria Gonzalez-Angulo (kl) Ana Maria Gonzalez-Angulo (nb) Ana Maria Gonzalez-Angulo (nl) Ana Maria Gonzalez-Angulo (nn) Ana Maria Gonzalez-Angulo (sv)
name	Ana Maria Gonzalez-Angulo (da) Ana Maria Gonzalez-Angulo (de) Ana Maria Gonzalez-Angulo (en) Ana Maria Gonzalez-Angulo (fo) Ana Maria Gonzalez-Angulo (fr) Ana Maria Gonzalez-Angulo (is) Ana Maria Gonzalez-Angulo (kl) Ana Maria Gonzalez-Angulo (nb) Ana Maria Gonzalez-Angulo (nl) Ana Maria Gonzalez-Angulo (nn) Ana Maria Gonzalez-Angulo (sv)
LinkedIn personal profile ID	wds:Q107718318-e4dd7cb6-4ed4-5f85-a350-b4dd37a92743
LinkedIn personal profile ID	ana-maria-gonzalez-angulo-926b2327
given name	wds:Q107718318-8BE5D9F6-0832-4B52-A1DB-356257B84555
given name	Ana
instance of	wds:Q107718318-c49ac67c-428f-1b58-8b19-7ed7294185fc
instance of	Homo sapiens
skos:altLabel	A M Gonzalez-Angulo (da) A M Gonzalez-Angulo (en) Ana M Gonzalez-Angulo (da) Ana M Gonzalez-Angulo (en)
occupation	wds:Q107718318-362f3e0f-4b07-016e-b5b7-81f7bde92518
significant event	wds:Q107718318-54c0c9bf-463a-59bb-befb-7f0d98fb1d2d
occupation	cancer researcher
significant event	conviction
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q107718318
is author of	Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer Earlier age of onset of BRCA mutation-related cancers in subsequent generations cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors Targeted therapies: peaking beneath the surface of recent bevacizumab trials Overview of resistance to systemic therapy in patients with breast cancer The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer Biomarkers of response to Akt inhibitor MK-2206 in breast cancer Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy Identifying factors that impact survival among women with inflammatory breast cancer Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts Concordance of genomic alterations between primary and recurrent breast cancer. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer cMET and phospho-cMET protein levels in breast cancers and survival outcomes Everolimus in the treatment of hormone receptor-positive breast cancer ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer Prognostic value of initial clinical disease stage after achieving pathological complete response Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications Effect of CYP2D6 polymorphisms on breast cancer recurrence. Metformin: a therapeutic opportunity in breast cancer Future of personalized medicine in oncology: a systems biology approach Targeting the hepatocyte growth factor-cMET axis in cancer therapy Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer Breast cancer subtype and baseline characteristics from diabetic breast cancer patients are not different from nondiabetics. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software